In 2015, drugs that were licensed as branded generics accounted for almost 79 percent of cardiovascular pharmaceutical sales in the Philippines. Cardiovascular diseases are the leading causes of death in the Philippines. In 2017, there were approximately 51 thousand deaths due to
Market share of licenses in the cardiovascular pharmaceutical sales in the Philippines from 2007 to 2015, by type
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Top pharmaceutical drugs
Global overview
3
Top companies' top products
5
- Premium Statistic Pfizer's top products based on revenue 2023
- Premium Statistic AbbVie's key product revenues 2022-2023
- Premium Statistic Sales of Johnson & Johnson's pharmaceutical products 2021-2023
- Premium Statistic Novartis' top drugs based on revenue 2023
- Premium Statistic Merck & Co.'s top-selling drugs 2023
Best-selling drugs
7
- Basic Statistic Top pharmaceutical products by sales worldwide 2023
- Premium Statistic Revenue of AbbVie's Humira 2011-2023
- Premium Statistic Merck & Co.'s Keytruda revenue 2014-2023
- Premium Statistic Bristol Myers Squibb's Revlimid revenues 2008-2023
- Premium Statistic Price increase of top selling drugs U.S. 2016-2021
- Basic Statistic Number of patent applications filed for top U.S. drugs 2022
- Premium Statistic Number of patents granted for the top selling U.S. drugs 2022
U.S. overview
5
- Premium Statistic Top pharma products by prescriptions U.S. 2021
- Premium Statistic Top therapy areas in the U.S. by number of prescriptions 2022
- Premium Statistic U.S. top prescribed drugs based on sales 2022
- Premium Statistic Total savings of top generic drugs in U.S. 2022
- Premium Statistic Sales at risk of pharmaceuticals due to patent expiries U.S. 2022
Outlook
5
- Basic Statistic Top therapeutic categories worldwide 2024, by number of R&D products
- Basic Statistic Projected most valuable R&D projects based on net present value 2023
- Premium Statistic Projection of top 2024 pharma and biotech launches by revenue 2028
- Premium Statistic Expiring patents for blockbuster and other small-molecule drugs worldwide 2020-2026
- Premium Statistic Sales forecast of top selling drugs worldwide 2028
Further related statistics
9
- Merck & Co total assets 2009-2023
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Global pharmaceutical pipeline by therapy area 2013-2017
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co cash dividends declared 2006-2023
- Pfizer's ad spending 2006-2023
- Johnson & Johnson's number of employees 2004-2023
- CVS Health's total assets 2005-2023
Further Content: You might find this interesting as well
Statistics
- Merck & Co total assets 2009-2023
- Sanofi's total assets 2007-2023
- Pfizer's revenues in the U.S. and abroad 2009-2023
- Global pharmaceutical pipeline by therapy area 2013-2017
- Merck & Co - expenditure on research and development 2006-2023
- Merck & Co cash dividends declared 2006-2023
- Pfizer's ad spending 2006-2023
- Johnson & Johnson's number of employees 2004-2023
- CVS Health's total assets 2005-2023
PCC. (June 8, 2020). Market share of licenses in the cardiovascular pharmaceutical sales in the Philippines from 2007 to 2015, by type [Graph]. In Statista. Retrieved June 17, 2024, from https://www.statista.com/statistics/1196445/philippines-market-share-of-licenses-in-cardiovascular-drug-by-type/
PCC. "Market share of licenses in the cardiovascular pharmaceutical sales in the Philippines from 2007 to 2015, by type." Chart. June 8, 2020. Statista. Accessed June 17, 2024. https://www.statista.com/statistics/1196445/philippines-market-share-of-licenses-in-cardiovascular-drug-by-type/
PCC. (2020). Market share of licenses in the cardiovascular pharmaceutical sales in the Philippines from 2007 to 2015, by type. Statista. Statista Inc.. Accessed: June 17, 2024. https://www.statista.com/statistics/1196445/philippines-market-share-of-licenses-in-cardiovascular-drug-by-type/
PCC. "Market Share of Licenses in The Cardiovascular Pharmaceutical Sales in The Philippines from 2007 to 2015, by Type." Statista, Statista Inc., 8 Jun 2020, https://www.statista.com/statistics/1196445/philippines-market-share-of-licenses-in-cardiovascular-drug-by-type/
PCC, Market share of licenses in the cardiovascular pharmaceutical sales in the Philippines from 2007 to 2015, by type Statista, https://www.statista.com/statistics/1196445/philippines-market-share-of-licenses-in-cardiovascular-drug-by-type/ (last visited June 17, 2024)
Market share of licenses in the cardiovascular pharmaceutical sales in the Philippines from 2007 to 2015, by type [Graph], PCC, June 8, 2020. [Online]. Available: https://www.statista.com/statistics/1196445/philippines-market-share-of-licenses-in-cardiovascular-drug-by-type/